These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 17606717

  • 1. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
    Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P.
    Clin Cancer Res; 2007 Jul 01; 13(13):3855-9. PubMed ID: 17606717
    [Abstract] [Full Text] [Related]

  • 2. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes-Funes H, Sanchez-Cespedes M.
    J Clin Oncol; 2006 Sep 10; 24(26):4333-9. PubMed ID: 16896002
    [Abstract] [Full Text] [Related]

  • 3. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U, Metzger R, Miyazono F, Baldus SE, Neiss S, Brabender J, Schaefer H, Doerfler W, Bollschweiler E, Dienes HP, Mueller RP, Danenberg PV, Hoelscher AH, Schneider PM.
    Clin Cancer Res; 2004 Jun 01; 10(11):3794-9. PubMed ID: 15173087
    [Abstract] [Full Text] [Related]

  • 4. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 5. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
    Darcy KM, Tian C, Reed E.
    Cancer Res; 2007 May 01; 67(9):4474-81. PubMed ID: 17483363
    [Abstract] [Full Text] [Related]

  • 6. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 01; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
    Shiga H, Heath EI, Rasmussen AA, Trock B, Johnston PG, Forastiere AA, Langmacher M, Baylor A, Lee M, Cullen KJ.
    Clin Cancer Res; 1999 Dec 01; 5(12):4097-104. PubMed ID: 10632346
    [Abstract] [Full Text] [Related]

  • 8. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 9. ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation.
    Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE.
    Anticancer Res; 2011 Dec 20; 31(12):4135-9. PubMed ID: 22199271
    [Abstract] [Full Text] [Related]

  • 10. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin.
    Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL.
    Jpn J Clin Oncol; 2010 Apr 20; 40(4):286-93. PubMed ID: 20085902
    [Abstract] [Full Text] [Related]

  • 11. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
    Fouret P, Temam S, Charlotte F, Lacau-St-Guily J.
    Br J Cancer; 2002 Dec 02; 87(12):1390-5. PubMed ID: 12454767
    [Abstract] [Full Text] [Related]

  • 12. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer.
    Lee HW, Han JH, Kim JH, Lee MH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC, Sheen SS, Lim HY.
    Lung Cancer; 2008 Jan 02; 59(1):95-104. PubMed ID: 17889401
    [Abstract] [Full Text] [Related]

  • 13. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy.
    Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB.
    Clin Cancer Res; 2008 Jul 01; 14(13):4225-31. PubMed ID: 18594004
    [Abstract] [Full Text] [Related]

  • 14. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May 01; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 15. Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.
    Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC, Sheen SS.
    Lung Cancer; 2010 May 01; 68(2):288-94. PubMed ID: 19560836
    [Abstract] [Full Text] [Related]

  • 16. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 01; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 17. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.
    Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, Hahner S, Allolio B, Fassnacht M.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):907-18. PubMed ID: 19240185
    [Abstract] [Full Text] [Related]

  • 18. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE, Danenberg PV, Harpole DH.
    Clin Cancer Res; 2005 Mar 15; 11(6):2215-21. PubMed ID: 15788669
    [Abstract] [Full Text] [Related]

  • 19. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 15; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 20. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct 15; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.